BlackRock
MPLT

BlackRock’s MapLight Therapeutics MPLT Stock Holding History

BlackRock’s Portfolio MPLT Stock Details MPLT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$36.7M Sell
1,025,134
-314,597
-23% -$9.05M ﹤0.01% 2874
2026
Q1 		$27.2M Buy
1,339,731
+244,217
+22% +$4.37M ﹤0.01% 2883
2025
Q4 		$19.2M Buy
+1,095,514
New +$18.4M ﹤0.01% 3126

Other funds holding MPLT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.51% 1-Year Est. Return

BlackRock's MPLT Position: Q2 2026 in Review

BlackRock reduced its MapLight Therapeutics (MPLT) stake by 23% in Q2 2026, selling an estimated $9.05M and leaving 1,025,134 shares worth $36.7M. The position accounts for ﹤0.01% of the portfolio, ranked #2874.

BlackRock first reported a position in MPLT in Q4 2025 and has held it in 3 quarters since. 100 funds tracked by Wall St. Rank hold MPLT as of Q2 2026.

  • BlackRock held 1,025,134 shares of MapLight Therapeutics worth $36.7M as of Q2 2026.
  • BlackRock sold 314,597 MapLight Therapeutics shares in Q2 2026, an estimated $9.05M.
  • MapLight Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #2874 holding.
  • BlackRock first reported a position in MapLight Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 100 funds tracked by Wall St. Rank held MapLight Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.